{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:40:38Z","timestamp":1768894838444,"version":"3.49.0"},"reference-count":28,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v102.2926","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T08:28:45Z","timestamp":1660638525000},"page":"adv00780","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series"],"prefix":"10.2340","volume":"102","author":[{"given":"Federica","family":"Repetto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Burzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"21684","doi-asserted-by":"crossref","unstructured":"Jiang SW, Whitley MJ, Mariottoni P, Jaleel T, MacLeod AS. Hidradenitis suppurativa: host-microbe and immune patho\u00adgenesis underlie important future directions. JID Innov 2021; 1: 100001.","DOI":"10.1016\/j.xjidi.2021.100001"},{"key":"21685","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.xjidi.2021.100001","DOI":"10.1016\/j.xjidi.2021.100001"},{"key":"21686","doi-asserted-by":"crossref","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016; 375: 422-434.","DOI":"10.1056\/NEJMoa1504370"},{"key":"21687","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1504370","DOI":"10.1056\/NEJMoa1504370"},{"key":"21688","doi-asserted-by":"crossref","unstructured":"Kelly G, Hughes R, McGarry T, van den Born M, Adamzik K, Fitzgerald R, et al. Dysregulated cytokine expression in lesional and non lesional skin in hidradenitis suppurativa. Br J Dermatol 2015; 173: 1431-1439.","DOI":"10.1111\/bjd.14075"},{"key":"21689","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.14075","DOI":"10.1111\/bjd.14075"},{"key":"21690","doi-asserted-by":"crossref","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790-798.","DOI":"10.1016\/j.jaad.2010.07.010"},{"key":"21691","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2010.07.010","DOI":"10.1016\/j.jaad.2010.07.010"},{"key":"21692","doi-asserted-by":"crossref","unstructured":"Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis 2021; 12: 20406223211055920.","DOI":"10.1177\/20406223211055920"},{"key":"21693","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/20406223211055920","DOI":"10.1177\/20406223211055920"},{"key":"21694","doi-asserted-by":"crossref","unstructured":"Montero-Vilchez T, Pozo-Rom\u00e1n T, S\u00e1nchez-Velicia L, Vega-Guti\u00e9rrez J, Arias-Santiago S, Molina-Leyva A. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat 2022; 33: 348-353.","DOI":"10.1080\/09546634.2020.1755008"},{"key":"21695","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2020.1755008","DOI":"10.1080\/09546634.2020.1755008"},{"key":"21696","doi-asserted-by":"crossref","unstructured":"Sharon VR, Garcia MS, Bagheri S, Goodarzi H, Yang C, Ono Y, Maverakis E. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 2012; 92: 320-321.","DOI":"10.2340\/00015555-1229"},{"key":"21697","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1229","DOI":"10.2340\/00015555-1229"},{"key":"21698","doi-asserted-by":"crossref","unstructured":"Blok JL, Li K, Brodmerkel C, Horv\u00e1tovich P, Jonkman MF, Horv\u00e1th B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 2016; 174: 839-846.","DOI":"10.1111\/bjd.14338"},{"key":"21699","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.14338","DOI":"10.1111\/bjd.14338"},{"key":"21700","doi-asserted-by":"crossref","unstructured":"Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019; 33: e140-e141.","DOI":"10.1111\/jdv.15368"},{"key":"21701","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15368","DOI":"10.1111\/jdv.15368"},{"key":"21702","doi-asserted-by":"crossref","unstructured":"Burzi L, Repetto F, Ramondetta A, Rozzo G, Licciardello M, Ribero S, et al. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? Dermatol Ther 2021; 34: 14930.","DOI":"10.1111\/dth.14930"},{"key":"21703","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14930","DOI":"10.1111\/dth.14930"},{"key":"21704","doi-asserted-by":"crossref","unstructured":"Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Arias-Santiago S, Molina-Leyva A. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review. Dermatol Ther 2020; 33: 13456.","DOI":"10.1111\/dth.13456"},{"key":"21705","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13456","DOI":"10.1111\/dth.13456"},{"key":"21706","doi-asserted-by":"crossref","unstructured":"Marques E, Arenberger P, Smetanov\u00e1 A, Gkalpakiotis S, Zimov\u00e1 D, Arenbergerov\u00e1 M. Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha. Br J Dermatol 2021; 184: 966-967.","DOI":"10.1111\/bjd.19716"},{"key":"21707","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19716","DOI":"10.1111\/bjd.19716"},{"key":"21708","doi-asserted-by":"crossref","unstructured":"Caposiena Caro RD, Pensa C, Lambiase S, Candi E, Bianchi L. Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures. Dermatol Ther 2021; 34: 15116.","DOI":"10.1111\/dth.15116"},{"key":"21709","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15116","DOI":"10.1111\/dth.15116"},{"key":"21710","doi-asserted-by":"crossref","unstructured":"Licata G, Gambardella A, Buononato D, De Rosa A, Calabrese G, Pellerone S, et al. A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab. Int J Dermatol 2021; 61: 126-129.","DOI":"10.1111\/ijd.15704"},{"key":"21711","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.15704","DOI":"10.1111\/ijd.15704"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2926\/7289","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2926\/7290","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2926\/7289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T09:13:29Z","timestamp":1664356409000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/2926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.2926","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}